These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 28756723)

  • 1. Novel pharmacological treatments for children and adolescents with heterozygous familial hypercholesterolemia.
    Wiegman A; Hutten BA
    Expert Rev Clin Pharmacol; 2017 Sep; 10(9):919-921. PubMed ID: 28756723
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical determinants and treatment gaps in familial hypercholesterolemia: Data from a multi-ethnic regional health service.
    Zafrir B; Jubran A; Lavie G; Halon DA; Flugelman MY; Shapira C
    Eur J Prev Cardiol; 2017 May; 24(8):867-875. PubMed ID: 28186442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma lipoprotein(a) levels and LDL-cholesterol lowering response to statin therapy in patients with heterozygous familial hypercholesterolemia.
    Miltiadous G; Saougos V; Cariolou M; Elisaf MS
    Ann Clin Lab Sci; 2006; 36(3):353-5. PubMed ID: 16951279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Familial hypercholesterolemia: current treatment and advances in management.
    Huijgen R; Vissers MN; Defesche JC; Lansberg PJ; Kastelein JJ; Hutten BA
    Expert Rev Cardiovasc Ther; 2008 Apr; 6(4):567-81. PubMed ID: 18402545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel treatment options for the management of heterozygous familial hypercholesterolemia.
    Polychronopoulos G; Tziomalos K
    Expert Rev Clin Pharmacol; 2017 Dec; 10(12):1375-1381. PubMed ID: 28884604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial.
    Thomas GS; Cromwell WC; Ali S; Chin W; Flaim JD; Davidson M
    J Am Coll Cardiol; 2013 Dec; 62(23):2178-84. PubMed ID: 24013058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Premature cardiovascular disease in young women with heterozygous familial hypercholesterolemia.
    van der Graaf A; Hutten BA; Kastelein JJ; Vissers MN
    Expert Rev Cardiovasc Ther; 2006 May; 4(3):345-51. PubMed ID: 16716095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.
    Raal F; Scott R; Somaratne R; Bridges I; Li G; Wasserman SM; Stein EA
    Circulation; 2012 Nov; 126(20):2408-17. PubMed ID: 23129602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 3-year study of atorvastatin in children and adolescents with heterozygous familial hypercholesterolemia.
    Langslet G; Breazna A; Drogari E
    J Clin Lipidol; 2016; 10(5):1153-1162.e3. PubMed ID: 27678432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of familial hypercholesterolemia in children and adolescents. Position paper of the Polish Lipid Expert Forum.
    Myśliwiec M; Walczak M; Małecka-Tendera E; Dobrzańska A; Cybulska B; Filipiak K; Mazur A; Jarosz-Chobot P; Szadkowska A; Rynkiewicz A; Chybicka A; Socha P; Brandt A; Bautembach-Minkowska J; Zdrojewski T; Limon J; Gidding SS; Banach M
    J Clin Lipidol; 2014; 8(2):173-80. PubMed ID: 24636176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel treatments for familial hypercholesterolemia: pharmacogenetics at work.
    Marbach JA; McKeon JL; Ross JL; Duffy D
    Pharmacotherapy; 2014 Sep; 34(9):961-72. PubMed ID: 24899514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia: 5-Year SAFEHEART Registry Follow-Up.
    Perez de Isla L; Alonso R; Watts GF; Mata N; Saltijeral Cerezo A; Muñiz O; Fuentes F; Diaz-Diaz JL; de Andrés R; Zambón D; Rubio-Marin P; Barba-Romero MA; Saenz P; Sanchez Muñoz-Torrero JF; Martinez-Faedo C; Miramontes-Gonzalez JP; Badimón L; Mata P;
    J Am Coll Cardiol; 2016 Mar; 67(11):1278-85. PubMed ID: 26988947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bempedoic Acid for Heterozygous Familial Hypercholesterolemia: From Bench to Bedside.
    Agarwala A; Quispe R; Goldberg AC; Michos ED
    Drug Des Devel Ther; 2021; 15():1955-1963. PubMed ID: 34007155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microsomal transfer protein inhibitors, new approach for treatment of familial hypercholesterolemia, review of the literature, original findings, and clinical significance.
    Kolovou G; Vasiliadis I; Gontoras N; Kolovou V; Hatzigeorgiou G
    Cardiovasc Ther; 2015 Apr; 33(2):71-8. PubMed ID: 25604780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of familial hypercholesterolaemia in children and adolescents in the last three decades.
    Elis A; Zhou R; Stein EA
    Cardiol Young; 2014 Jun; 24(3):437-41. PubMed ID: 23659280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of lipid-lowering treatment on natural history of heterozygous familial hypercholesterolemia in past three decades.
    Elis A; Zhou R; Stein EA
    Am J Cardiol; 2011 Jul; 108(2):223-6. PubMed ID: 21545982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Colesevelam: in pediatric patients with heterozygous familial hypercholesterolemia.
    Perry CM
    Paediatr Drugs; 2010 Apr; 12(2):133-40. PubMed ID: 20218749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors Associated With Low-Density Lipoprotein Cholesterol Reduction in Patients With Familial Hypercholesterolemia: Results From Isfahan Familial Hypercholesterolemia Registry.
    Vaseghi G; Jamalin M; Arabi S; Kheiri S; Hajian S; Sarrafzadegan N
    Am J Ther; 2020; 27(2):e227-e228. PubMed ID: 31815752
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of familial hypercholesterolemia in children and adolescents: effect of lovastatin. Canadian Lovastatin in Children Study Group.
    Lambert M; Lupien PJ; Gagné C; Lévy E; Blaichman S; Langlois S; Hayden M; Rose V; Clarke JT; Wolfe BM; Clarson C; Parsons H; Stephure DK; Potvin D; Lambert J
    Pediatrics; 1996 May; 97(5):619-28. PubMed ID: 8628597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia.
    Rader DJ; Kastelein JJ
    Circulation; 2014 Mar; 129(9):1022-32. PubMed ID: 24589695
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.